Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H1N1)pdm09 influenza: A multicenter study of the 2024–2025 season
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H1N1)pdm09 influenza: A multicenter study of the 2024–2025 season. // Journal of Infection and Chemotherapy. – URL: https://www.sciencedirect.com/science/article/pii/S1341321X26002102?dgcid=rss_sd_all
Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H1N1)pdm09 influenza: A multicenter study of the 2024–2025 season. Journal of Infection and Chemotherapy. https://www.sciencedirect.com/science/article/pii/S1341321X26002102?dgcid=rss_sd_all
“Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H1N1)pdm09 influenza: A multicenter study of the 2024–2025 season.” Journal of Infection and Chemotherapy.
@article{article53661,
title = {Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H1N1)pdm09 influenza: A multicenter study of the 2024–2025 season},
journal = {Journal of Infection and Chemotherapy},
url = {https://www.sciencedirect.com/science/article/pii/S1341321X26002102?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...